Brown Advisory’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Brown Advisory’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,733	Closed	-$285K	–	1264
2017 Q2	$285K	Buy	+4,733	New	+$270K	﹤0.01%	1029

Other funds holding BIVV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brown Advisory's BIVV Position: Q3 2017 in Review

Brown Advisory sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 4,733 shares — an estimated $285K sold.

Brown Advisory first reported a position in BIVV in Q2 2017 and held it in 1 quarter. The position peaked at $285K in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

Brown Advisory reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Brown Advisory sold 4,733 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $285K.
Brown Advisory first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 1 quarter.
Brown Advisory's Bioverativ Inc. Common Stock position peaked at $285K in Q2 2017.
446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Brown Advisory's 13F filing for Q3 2017, filed 13 Nov 2017.